Jamjoom Pharmaceuticals Factory Co. · TADAWUL:4015

Jamjoom Pharmaceuticals Factory — Q1 2026 Earnings Presentation

15 slides from Jamjoom Pharmaceuticals Factory's earnings presentation, Apr 23, 2026

  1. Slide 1: Earnings Presentation 1Q 2026

    Earnings Presentation 1Q 2026 Jeddah | 23 April 2026

  2. Slide 2: Disclaimer

    2 Disclaimer This presentation has been prepared solely for use as an investor presentation for Jamjoom Pharmaceuticals Factory Company (the “Company”). By attending or by reading this presentation, you agree to be bound by the following limitations. The information contained in this presentation is

  3. Slide 3: Business and Strategy Highlights

    Business and Strategy Highlights Tarek Hosni, CEO

  4. Slide 4: 1Q 2026 Highlights: Sustained Profitability Through Disciplined Execution

    4 Business and Strategy Highlights 1Q 2026 Highlights: Sustained Profitability Through Disciplined Execution Revenue Our strongest quarterly sales performance to # of Brands date, underpinned by continued success in 2026 new launches on-track to commercialize in 1Q 26 +5% YoY 1Q 26 strategic deliver

  5. Slide 5: Operational Momentum and Portfolio Progress Amid Market and Geopolitical Challenges

    5 Business and Strategy Highlights Operational Momentum and Portfolio Progress Amid Market and Geopolitical Challenges • YTD February, Saudi Retail Market1 declined by 6.9% (JP down 2%) • MAT February, Saudi Retail Market1 grew 8.6% (JP up 23%) Saudi Market • Post strong 1Q25 growth (~150% vs 1Q24),

  6. Slide 6: Consistent Growth Across Core TAs and Markets

    6 Business and Strategy Highlights Consistent Growth Across Core TAs and Markets Revenue Contribution by Therapeutic Area, YoY (SARmn) Revenue Contribution by Country, YoY (SARmn) +5% +5% 458 18 5 2 481 14 14 481 458 12 (1) (0) Iraq revenue decline reflects Egypt recorded a slight YoY (11) (6) logis

  7. Slide 7: Portfolio Transformation: From Niche Specialty to Diversified, High-Value TAs

    7 Business and Strategy Highlights Portfolio Transformation: From Niche Specialty to Diversified, High-Value TAs 2021 Revenue Contribution by Therapeutic Area (SARmn) 1Q 2026 Revenue Contribution by Therapeutic Area (SARmn) Consumer Health Consumer Health Ophthalmology 10% Ophthalmology 10% 27% 32%

  8. Slide 8: Update on JP's Strategic Potential Initiatives

    8 Business and Strategy Highlights Update on JP’s Strategic Potential Initiatives • Localization of Vaccines and Biologicals JV with PIF (Lifera) • Current status: Shareholder Agreement finalization • Exploring potential acquisitions to enhance future capacity growth Manufacturing Expansion • Announ

  9. Slide 9: Financial Highlights

    Financial Highlights Anwer Mohiuddin, CFO

  10. Slide 10: Disciplined Cost Management to Support Business Growth

    10 Financial Highlights Disciplined Cost Management to Support Business Growth Total Cost Of Revenue Movement YoY (SARmn) Operating Expenses Movement YoY (SARmn) +2% +4% 132 2 1 0 135 2 1 0 171 165 2 Through targeted, high-impact spending and controlled cost discipline, JP absorbed inflation and emp

  11. Slide 11: Expanding Margins Through Solid Revenue Delivery and Cost Efficiencies

    11 Financial Highlights Expanding Margins Through Solid Revenue Delivery and Cost Efficiencies EBITDA Movement YoY (SARmn) +8% EBITDA Margin EBITDA Margin 37.7% 38.8% 24 187 172 (6) (2) (1) (0) +5% +4% +2% +6% -1% 1Q 25 Revenue Cost of revenue Selling & distribution expenses General & administration

  12. Slide 12: Scaling Working Capital to Support Continuous Growth

    12 Financial Highlights Scaling Working Capital to Support Continuous Growth ▪ Improved inventory days drove a reduction in the cash conversion cycle (CCC) to 279 Cash Conversion Cycle (Days) days (-2% YoY), despite higher receivable days (DSO) which were offset by a reduction in inventory days (DIO

  13. Slide 13: Outlook and Guidance

    Jamjoom Pharma LojLé pgaa Outlook and Guidance

  14. Slide 14: Financial Guidance: Guidance Maintained Though Challenging Geopolitical Landscape

    14 Outlook and Guidance Financial Guidance: Guidance Maintained Though Challenging Geopolitical Landscape FY 26-27 Guidance Revenue growth 10-12% (CAGR) EBITDA margin 33-35% CAPEX 6-9% Dividend 50-60% payout subject to optimum capital allocation decision (semi-annual) Jamjoom Earnings Presentation -

  15. Slide 15: Q&A

    Q&A Tarek Hosni, Chief Executive Officer Anwer Mohiuddin, Chief Financial Officer Muhammad Bin Khalid, Assoc. Director – Finance & IR

Jamjoom Pharmaceuticals Factory — Q1 2026 Earnings Presentation on 6ix